ESMO 2025 special: Prof. Roupret presents the ALBAN study

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Morgan Roupret (FR), on the results of the ALBAN trial. A phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG naïve high-risk, non-muscle invasive bladder cancer. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa. For more EAU podcasts, ...